Medical beauty business, Aestura, is selling off its filler brand Cleviel to Pharma Research Products. The move comes as Amorepacific develops its inroads in the anti-ageing and regenerative medicine sectors.
Headed up by Lim Woonsup, CEO, the Amorepacific Group affiliate has entered into an MOU with Pharma Research Products, led by CEOs Jung Sangsoo and Ahn Wonjun.
Signed on 11th January 2018, the recent agreement will see the two Asia heavyweights formally conclude the transfer of Clevial by its scheduled transfer date of February 2018.
As part of the MoU, Aestura will sell both Cleviel’s business rights and related technology to Pharma Research Products.
A social impact
Medical beauty company Aestura promotes its brand as one with a social conscience as it aims to deliver healthy beauty. Its core business purposes focus on both aesthetic and derma cosmetics.
Hyaluronic acid filler brand Cleviel reflects these values and brand identifiers by using medical equipment and biomaterials for tissue repair and the temporary improvement of facial wrinkles.
Pharma Research applies its R&D and manufacturing efforts to regenerative science to improve quality of life for its ageing society. Headquartered in South Korea, the company’s research to date has led to the development of DNA fragments, PDRN and PN. The fragments were isolated from reproductive organs of wild Korean salmons.
These crucially assist in the regeneration of damaged tissues and organ by repairing and regenerating age-related damaged and exhausted tissue and organ.
Amorepacific Group’s wider strategy is geared towards ploughing resources into the medical beauty sector including derma cosmetics. Looking to the future, it also plans to “continue to invest in and foster Aestura as a pioneer in the global medical beauty industry”, Amorepacific announced.
Aestura is a core part of this overall longer-term plan as Amorepacific hopes to use medical and clinical channels to drive innovation, and become the “hidden champion of medical beauty in Asia”.